A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors - Becher, Oren J.; Gilheeney, Stephen W.; Khakoo, Yasmin; Lyden, David C.; Haque, Sofia; Braganca, Kevin C.; Kolesar, Jill M.; Huse, Jason T.; Modak, Shakeel; Wexler, Leonard H.; Kramer, Kim; Spasojevic, Ivan; et al. (Pediatric blood & cancer, 2017)
Keywords: 1-Phosphatidylinositol 3-kinase; Adolescent; Age; AKT; AKT protein; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics; Brain cancer; Brain tumors; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Glioma; Hematology; Humans; Hypercholesterolemia; Inhibitor drugs; Lymphopenia; Male; Maximum Tolerated Dose; Medulloblastoma; mTOR; Neoplasm Recurrence, Local - drug therapy; Neoplasms - drug therapy; Neuroblastoma; Neutropenia; Oncology; Pediatrics; perifosine; Pharmacokinetics; phase I clinical trials; Phosphorylcholine - administration & dosage; Phosphorylcholine - adverse effects; Phosphorylcholine - analogs & derivatives; Phosphorylcholine - pharmacokinetics; Rhabdomyosarcoma; Sirolimus - administration & dosage; Sirolimus - adverse effects; Sirolimus - analogs & derivatives; Sirolimus - pharmacokinetics; Solid tumors; Targeted cancer therapy; temsirolimus; Thrombocytopenia; TOR protein; Toxicity; Young Adult; mTOR; AKT; temsirolimus; phase I clinical trials; perifosine